A Study of Monthly Risedronate for Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,294

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

risedronate

tablet, 5 mg risedronate, once a day for 2 years

DRUG

risedronate

oral, 150 mg risedronate, once a month for 2 years

Trial Locations (49)

10983

Research Site, West Haverstraw

20817

Research Site, Bethesda

30501

Research Site, Gainesville

45219

Research Site, Cincinnati

80227

Research Site, Lakewood

97212

Research Site, Portland

068131

Research Site, Omaha

Unknown

Research Site, Buenos Aires

Research Site, Capital Federal

Research Site, Geelong

Research Site, Heidelberg, Victoria

Research Site, Saint Leonards

Research Site, Brussels

Research Site, Ghent

Research Site, Leuven

Research Site, Liège

Research Site, Mont Godinne

Research Site, Rio de Janeiro

Research Site, São Paulo

Research Site, Calgary

Research Site, Montreal

Research Site, Sainte-Foy

Research Site, Saskatoon

Research Site, Pärnu

Research Site, Tartu

Research Site, Helsinki

Research Site, Kuopio

Research Site, Oulu

Research Site, Turku

Research Site, Amiens

Research Site, Lyon

Research Site, Orléans

Research Site, Paris

Research Site, Toulouse

Research Site, Vandœuvre-lès-Nancy

Research Site, Balatonfüred

Research Site, Budapest

Research Site, Győr

Research Site, Miskolc

Research Site, Nagykanizs

Research Site, Beirut

Research Site, Oslo

Research Site, Paradis

Research Site, Trondheim

Research Site, Bialystok

Research Site, Warsaw

Research Site, Barcelona

Research Site, Granada

Research Site, Madrid

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Warner Chilcott

INDUSTRY